Five Prime/Inhibrx Deal Has First ‘Breakthrough’ Milestone Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration on GITR immune checkpoint inhibitors includes an extra $100 million if candidates gain FDA breakthrough designation.